New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
New genetically-validated drug targets are found at accelerated speed using population scale biobank genotype-phenotype datasets after a foundational partnership is formed between Paradigm4 and Alnylam.
Single-cell analysis has great promise… but how can we get there? by Zachary Pitluk
Pharma researchers are tasked with organizing disparate data, which detracts from time spent understanding disease mechanisms and enabling the development of more effective drugs. Paradigm4 is tackling this issue with a new platform based on a novel approach to data organization and elastic computing. Even companies with small budgets can
Zachary Pitluk, Ph.D., Vice President of Life Sciences and Healthcare at Paradigm4, highlights how real insight comes, not from data collection, but from intelligent data curation, computation, and application.